---
category: news
title: "Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL(TM) in Prostate Cancer Achieved Primary Endpoint"
excerpt: "About PROGENICS Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find ... who require systemic anticancer therapy; and oral and subcutaneous formulations of RELISTOR [(R)] (methylnaltrexone bromide) for the treatment of opioid-induced constipation ..."
publishedDateTime: 2019-12-23T11:00:00Z
sourceUrl: https://www.marketwatch.com/press-release/progenics-pharmaceuticals-announces-phase-3-condor-trial-of-pyltm-in-prostate-cancer-achieved-primary-endpoint-2019-12-23-7184024
type: article
quality: 33
heat: 33
published: false

provider:
  name: MarketWatch
  domain: marketwatch.com
  images:
    - url: /assets/images/organizations/marketwatch.com-50x50.jpg
      width: 50
      height: 50

topics:
  - AI
  - AI in Healthcare

images:
  - url: https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png
    width: 1200
    height: 630
    title: "Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL(TM) in Prostate Cancer Achieved Primary Endpoint"

related:
  - title: "Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyLâ„¢ in Prostate Cancer Achieved Primary Endpoint"
    excerpt: "NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find ... conventional imaging and/or changes in PSA levels following radiation therapy. Safety results showed PyL was well tolerated, consistent with the Phase 2 OSPREY ..."
    publishedDateTime: 2019-12-23T15:49:00Z
    sourceUrl: https://finance.yahoo.com/news/progenics-pharmaceuticals-announces-phase-3-120010916.html
    type: article
    provider:
      name: YAHOO!
      domain: yahoo.com
    quality: 0

secured: "gv40SrbQ4LTqsvwDKSQwVGXVxLuDPpxG9GRcByZ9PsVqtR4Gqf1mGd3e0GTTS59r2FDIl8AxhOBy673oo6Wl6FVTKXzuViQ2itnv1Gpg5qNg7uXk90vBjPZC8mYcQ570XEZTp6lSqo3dZs2tZgpE1ZSm58M8mPFEbfUciX+vHNYCZISn2rkrsdIcaOMpVrVhxvzPCMqoeiBBj9F3ULHnFBUcXQVsvZtFX2qY5/SkHIhv05wdQNOYTjKnf3nHUpubr7wCQoA7Ji2tdnx2WBEvqw==;3B9ZtlnxVCjSO3dDdbm07g=="
---

